^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
IPG7236
i
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Immunophage Biotech
Drug class:
CCR8 inhibitor
Related drugs:
13d
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=196, Recruiting, Nanjing Immunophage Biotech Co., Ltd | Phase classification: P1 --> P1/2
Phase classification
|
IPG7236
4ms
Phase1/2a Study for IPG7236 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=196, Recruiting, Nanjing Immunophage Biotech Co., Ltd | Trial completion date: Dec 2024 --> Dec 2025 | Trial primary completion date: Dec 2024 --> Sep 2025
Trial completion date • Trial primary completion date • Metastases
|
IPG7236
11ms
IPG7236 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=196, Recruiting, Nanjing Immunophage Biotech Co., Ltd | Trial completion date: Mar 2024 --> Dec 2024 | Trial primary completion date: Dec 2023 --> Dec 2024
Trial completion date • Trial primary completion date • Metastases
|
IPG7236
almost2years
Discovery of a Potent and Selective CCR8 Small Molecular Antagonist IPG7236 for the Treatment of Cancer. (PubMed, J Med Chem)
IPG7236 alone or in combination with PD-1 antibody exhibited significant tumor suppression effects in the mouse xenograft model of human breast cancer. IPG7236 is a promising clinical candidate that targets CCR8 with excellent in vitro ADMET properties, pharmacokinetics, safety profiles, and in vivo efficacy.
Journal
|
CCR8 (C-C Motif Chemokine Receptor 8)
|
IPG7236
Share via
